Ariad Pharmaceuticals Inc fka ARIA

[Au-530]

ARIAD to Present at the Jefferies 2011 Global Healthcare Conference
Last update: 6/1/2011 7:35:00 AM
CAMBRIDGE, Mass., Jun 01, 2011 (BUSINESS WIRE) -- ARIAD Pharmaceuticals, Inc. (ARIA) today announced that it will present at the Jefferies 2011 Global Healthcare Conference being held at the Grand Hyatt Hotel in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's strong oncology pipeline on Wednesday, June 8 at 9:30 a.m. (ET).
The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at . A replay of the presentation will also be available and archived on the site for 90 days.
About ARIAD
ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit .


http://custom.fmg.dowjones.com/custom/tdameritrade-com/html-story.asp?guid=%7B4f3715ef-dc6f-4eae-9db1-184ccd070e6e%7D